- NCIt
- C132146
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (101)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01435096 | BN80927 in Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 56 | IpsenINDUSTRY | 1 | Mar 3, 2020 | clinicaltrials |
| NCT04275050 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 19, 2020 | clinicaltrials |
| NCT03217253 |
| Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction |
| withdrawn |
| Phase 1 |
| 0 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Feb 7, 2020 |
| clinicaltrials |
| NCT02518958 | A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab(PRIMETIME) | completed | Phase 1 | 12 | EpicentRx, Inc.INDUSTRY | 1 | Nov 18, 2019 | clinicaltrials |
| NCT01648764 | A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread | completed | Phase 1 | 73 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 17, 2019 | clinicaltrials |
| NCT02045095 | A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors | terminated | Phase 1 | 29 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT01858155 | Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors | completed | Phase 1 | 9 | C17 CouncilOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT03618043 | Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer | unknown | Phase 1 | 14 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT01128842 | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor | completed | Phase 1 | 7 | Puma Biotechnology, Inc.INDUSTRY | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00768469 | Study Evaluating Safety And Tolerability, Solid Tumor | completed | Phase 1 | 10 | Puma Biotechnology, Inc.INDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT00997360 | Study of PKI-179 Administered Orally to Subjects With Solid Tumors | withdrawn | Phase 1 | 0 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Sep 27, 2018 | clinicaltrials |
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 92 | Puma Biotechnology, Inc.INDUSTRY | 11 | Aug 9, 2018 | clinicaltrials |
| NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | completed | Phase 1 / Phase 2 | 110 | Puma Biotechnology, Inc.INDUSTRY | 9 | Jul 26, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT00958724 | Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors | completed | Phase 1 | 6 | Puma Biotechnology, Inc.INDUSTRY | 1 | Jun 28, 2018 | clinicaltrials |
| NCT01820299 | Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer | completed | Phase 1 | 22 | Medical University of South CarolinaOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT01519817 | Cancer Vaccine Targeting Brachyury Protein in Tumors | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Jan 29, 2018 | clinicaltrials |
| NCT00728468 | A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients | completed | Phase 1 | 16 | PfizerINDUSTRY | 1 | Aug 2, 2017 | clinicaltrials |
| NCT00968981 | A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists | completed | Phase 1 | 67 | Genentech, Inc.INDUSTRY | 0 | Jul 11, 2017 | clinicaltrials |
| NCT00977067 | A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies | terminated | Phase 1 | 40 | Genentech, Inc.INDUSTRY | 0 | Jun 21, 2017 | clinicaltrials |
| NCT01670175 | Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors | completed | Phase 1 | 21 | University of California, San FranciscoOTHER | 1 | Jun 21, 2017 | clinicaltrials |
| NCT03171220 | Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors(NRT-01) | unknown | Phase 1 / Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT00954642 | A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 24 | Genentech, Inc.INDUSTRY | 0 | May 17, 2017 | clinicaltrials |
| NCT01721148 | A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours | completed | Phase 1 | 39 | ASLAN PharmaceuticalsOTHER | 0 | Jan 25, 2017 | clinicaltrials |
| NCT01611857 | Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | completed | Phase 1 / Phase 2 | 49 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT00876109 | A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | completed | Phase 1 | 108 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01075464 | A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 64 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01106599 | A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 61 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01139723 | A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors | completed | Phase 1 | 54 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01226277 | A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 42 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01332604 | GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 41 | Genentech, Inc.INDUSTRY | 2 | Nov 2, 2016 | clinicaltrials |
| NCT01598129 | ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers | completed | Phase 1 | 12 | Targovax OyINDUSTRY | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01325558 | A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 30 | Altor BioScienceINDUSTRY | 1 | Jul 15, 2016 | clinicaltrials |
| NCT01090960 | A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors | completed | Phase 1 | 52 | Genentech, Inc.INDUSTRY | 1 | Jul 4, 2016 | clinicaltrials |
| NCT01391533 | Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors(SARMET) | completed | Phase 1 | 72 | SanofiINDUSTRY | 4 | Apr 13, 2016 | clinicaltrials |
| NCT02096341 | A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001 | terminated | Phase 1 | 2 | EpicentRx, Inc.INDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01694472 | Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors | unknown | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 22, 2015 | clinicaltrials |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | terminated | Phase 1 | 9 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00388427 | Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies | completed | Phase 1 | 31 | University of PittsburghOTHER | 1 | May 28, 2015 | clinicaltrials |
| NCT01343498 | Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors | completed | Phase 1 | 33 | SCRI Development Innovations, LLCOTHER | 1 | May 1, 2015 | clinicaltrials |
| NCT00884845 | Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors | completed | Phase 1 | 35 | PharmaMarINDUSTRY | 2 | Mar 26, 2014 | clinicaltrials |
| NCT01184807 | Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors | completed | Phase 1 | 51 | Otsuka Beijing Research InstituteINDUSTRY | 1 | Mar 26, 2014 | clinicaltrials |
| NCT00725634 | A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma(P05538) | completed | Phase 1 | 41 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 27, 2014 | clinicaltrials |
| NCT00337376 | A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers | terminated | Phase 1 | 23 | Yale UniversityOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00551096 | Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors | completed | Phase 1 | 23 | University of Colorado, DenverOTHER | 1 | Dec 25, 2013 | clinicaltrials |
| NCT01951846 | To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours | completed | Phase 1 | 61 | Boehringer IngelheimINDUSTRY | 1 | Sep 27, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Mar 3, 2020source: clinicaltrials